# The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

> **NCT06827431** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 770 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** Ammoxetine
- **DRUG:** Ammoxetine
- **DRUG:** Placebo
- **DRUG:** Sertraline

## Key facts

- **NCT ID:** NCT06827431
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-14
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 770 (ESTIMATED)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06827431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06827431, "The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06827431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*